CD4+ T-cell effecters inhibit Epstein-Barr virus-induced B-cell proliferation

被引:64
作者
Nikiforow, S
Bottomly, K
Miller, G
机构
[1] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA
[3] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA
[4] Yale Univ, Sch Med, Dept Biochem & Mol Biophys, New Haven, CT 06520 USA
关键词
D O I
10.1128/JVI.75.8.3740-3752.2001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
In immunodeficient hosts, Epstein-Barr virus (EBV) often induces extensive B-cell lymphoproliferative disease and lymphoma. Without effective in vitro immune surveillance, B cells infected by the virus readily form immortalized cell lines. In the regression assay, memory T cells inhibit the formation of foci of EBV-transformed B cells that follows recent in vitro infection by EBV. No one has yet addressed which T cell regulates the early proliferative phase of B cells newly infected by EBV. Using new quantitative methods, we analyzed T-tell surveillance of EBV-mediated B-cell proliferation. We found that CD4(+) T cells play a significant role in limiting proliferation of newly infected, activated CD23(+) B cells. In the absence of T cells, EBV-infected CD23(+) B cells divided rapidly during the first 3 weeks after infection. Removal of CD4(+) but not CD8(+) T cells also abrogated immune control. Purified CD4(+) T cells eliminated outgrowth when added to EBV-infected B cells. Thus, unlike the killing of EBV-infected lymphoblastoid cell lines, in which CD8(+) cytolytic T cells play an essential role, prevention of early-phase EBV-induced B-cell proliferation requires CD4(+) effector T cells.
引用
收藏
页码:3740 / 3752
页数:13
相关论文
共 72 条
  • [1] LYMPHOCYTES ACTIVATED BY THE EPSTEIN-BARR VIRUS TO PRODUCE IMMUNOGLOBULIN DO NOT EXPRESS CD23 OR BECOME IMMORTALIZED
    AZIM, T
    CRAWFORD, DH
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1988, 42 (01) : 23 - 28
  • [2] Epstein-Barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients
    Babcock, GJ
    Decker, LL
    Freeman, RB
    Thorley-Lawson, DA
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (04) : 567 - 576
  • [3] Effect of cyclosporine and tacrolimus on the growth of Epstein-Barr virus-transformed B-cell lines
    Beatty, PR
    Krams, SM
    Esquivel, CO
    Martinez, OM
    [J]. TRANSPLANTATION, 1998, 65 (09) : 1248 - 1255
  • [4] Human CD8+ T cell responses to EBV EBNA1:: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing
    Blake, N
    Lee, S
    Redchenko, I
    Thomas, W
    Steven, N
    Leese, A
    Steigerwald-Mullen, P
    Kurilla, MG
    Frappier, L
    Rickinson, A
    [J]. IMMUNITY, 1997, 7 (06) : 791 - 802
  • [5] Bonnefoy J Y, 1997, Int Rev Immunol, V16, P113, DOI 10.3109/08830189709045705
  • [6] BOYLE TJ, 1993, SURGERY, V114, P218
  • [7] BOYLE TJ, 1992, SURGERY, V112, P378
  • [8] EPSTEIN-BARR-VIRUS (EBV) INDUCES EXPRESSION OF B-CELL ACTIVATION MARKERS ON INVITRO INFECTION OF EBV-NEGATIVE B-LYMPHOMA CELLS
    CALENDER, A
    BILLAUD, M
    AUBRY, JP
    BANCHEREAU, J
    VUILLAUME, M
    LENOIR, GM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (22) : 8060 - 8064
  • [9] Large clonal expansions of CD8(+) T cells in acute infectious mononucleosis
    Callan, MFC
    Steven, J
    Krausa, P
    Wilson, JDK
    Moss, PAH
    Gillespie, GM
    Bell, JI
    Rickinson, AB
    McMichael, AJ
    [J]. NATURE MEDICINE, 1996, 2 (08) : 906 - 911
  • [10] Cao S, 1999, Pediatr Transplant, V3, P22, DOI 10.1034/j.1399-3046.1999.00002.x